Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...
Publications
2 shownLong-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).
9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 6,112
- Institution
- Institut Català d'Oncologia
External Links
Identifiers
- ORCID
- 0000-0001-5235-5602
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.